Alyeska Investment Group
RGNX icon

Alyeska Investment Group’s Regenxbio RGNX Stock Holding History

Alyeska Investment Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-51,736
Closed -$1.14M – 456
2015
Q3 		$1.14M Buy
+51,736
New +$1.32M 0.01% 382

Other funds holding RGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Alyeska Investment Group's RGNX Position: Q4 2015 in Review

Alyeska Investment Group sold out of Regenxbio (RGNX) in Q4 2015, closing a stake of 51,736 shares — an estimated $1.14M sold.

Alyeska Investment Group first reported a position in RGNX in Q3 2015 and held it in 1 quarter. The position peaked at $1.14M in Q3 2015. 66 funds tracked by Wall St. Rank hold RGNX as of Q4 2015.

  • Alyeska Investment Group reported no remaining Regenxbio position as of Q4 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 51,736 Regenxbio shares in Q4 2015, an estimated $1.14M.
  • Alyeska Investment Group first reported a position in Regenxbio in Q3 2015 and held it in 1 quarter.
  • Alyeska Investment Group's Regenxbio position peaked at $1.14M in Q3 2015.
  • 66 funds tracked by Wall St. Rank held Regenxbio as of Q4 2015.

Based on Alyeska Investment Group's 13F filing for Q4 2015, filed 16 Feb 2016.